Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non–small-cell lung cancer, melanoma, and renal-cell cancer.
0.1 ml Concentrate - IHC001-100
1.0 ml Concentrate - IHC001-1
7.0 ml Pre-Dilute - IHC001-7
Source Mouse Monoclonal Positive Control Tonsil, Lymph Node Dilution Range 1:50-1:200
- Dorfman DM, et al. Am J Surg Pathol. 2006; 30:802-10.
- Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360-5.
- Kobayashi M, et al. J Rheumatol. 2005; 32:2156-63.
- Konishi J, et al. Clin Cancer Res. 2004; 10:5094-100.
- Mataki N, et al. Am J Gastroenterol. 2007; 102:302-12.
- Kim JW, et al. Oncology (Williston Park). 2014; 28:15-28.
- Tumeh PC, et al. Nature. 2014; 515:568-71.
- D’Incecco A, et al. Br J Cancer. 2015; 112:95-102.
- Tykodi SS. Onco Targets Ther. 2014; 7:1349-59.